{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:31:08Z","timestamp":1790742668974,"version":"4.1.0"},"reference-count":16,"publisher":"Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,13]]},"DOI":"10.31744\/einstein_journal\/2024ae1133","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T13:16:16Z","timestamp":1731590176000},"source":"Crossref","is-referenced-by-count":5,"title":["Longitudinal data collection in pediatric and adult patients with 5q spinal muscular atrophy in Latin America: LATAM RegistrAME study - a clinical registry study protocol"],"prefix":"10.31744","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7379-2480","authenticated-orcid":false,"given":"Elice Carneiro","family":"Batista","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4991-6760","authenticated-orcid":false,"given":"Edmar","family":"Zanoteli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9590-5448","authenticated-orcid":false,"given":"Frederico","family":"Monfardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4683-2851","authenticated-orcid":false,"given":"Gustavo Prado dos","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3247-3123","authenticated-orcid":false,"given":"Gisele Sampaio","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4972-2958","authenticated-orcid":false,"given":"Ot\u00e1vio","family":"Berwanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9949-9849","authenticated-orcid":false,"given":"Luiz Vicente","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8360-8465","authenticated-orcid":false,"given":"Henrique Andrade Rodrigues da","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16942","reference":[{"key":"key20241114131604_B1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1474-4422(12)70061-3","article-title":"Childhood spinal muscular atrophy: Controversies and challenges","volume":"11","author":"Mercuri","year":"2012","unstructured":"1. Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: Controversies and challenges. Lancet Neurol. 2012;11:443-52.","journal-title":"Lancet Neurol"},{"issue":"1","key":"key20241114131604_B2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","unstructured":"2. Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155-65.","journal-title":"Cell"},{"key":"key20241114131604_B3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/joa.12083","article-title":"Spinal muscular atrophy: a motor neuron disorder or a multiorgan disease?","volume":"224","author":"Shababi","year":"2014","unstructured":"3. Shababi M, Lorson CL, Rudnik-Schoneborn SS. Spinal muscular atrophy: a motor neuron disorder or a multiorgan disease? J Anat. 2014;224:15-28.","journal-title":"J Anat"},{"key":"key20241114131604_B4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy, part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","unstructured":"4. Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Mainet M, et al. Diagnosis and management of spinal muscular atrophy, part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28:103-15.","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"key20241114131604_B5","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","unstructured":"5. Finkel RS, McDermott MP, Kaufmann P, Darras BT, Chung WK, Sproule DM, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83(9):810-17.","journal-title":"Neurology"},{"key":"key20241114131604_B6","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1007\/s00415-008-0929-0","article-title":"A natural history study of late onset spinal muscular atrophy types 3b and 4","volume":"255","author":"Piepers","year":"2008","unstructured":"6. Piepers S, van den Berg LH, Brugman F, Ruiterkamp-Versteeg M, van Engelen BG. A natural history study of late onset spinal muscular atrophy types 3b and 4. J Neurol. 2008;255:1400-4.","journal-title":"J Neurol"},{"key":"key20241114131604_B7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy, part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","unstructured":"7. Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ. Diagnosis and management of spinal muscular atrophy, part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28:197-207.","journal-title":"Neuromuscul Disord"},{"issue":"18","key":"key20241114131604_B8","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","unstructured":"8. Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723-32.","journal-title":"N Engl J Med"},{"issue":"18","key":"key20241114131604_B9","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","unstructured":"9. Mendell JR, Al-Zaidy S, Shell R, Arnold D, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713-22.","journal-title":"N Engl J Med"},{"issue":"7","key":"key20241114131604_B10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","unstructured":"10. Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625-35.","journal-title":"N Engl J Med"},{"issue":"7","key":"key20241114131604_B11","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s00415-017-8549-1","article-title":"A multi-source approach to determine SMA incidence and research ready population","volume":"264","author":"Verhaart","year":"2017","unstructured":"11. Verhaart IEC, Robertson A, Leary R, McMacken G, K\u00f6nig K, Kirschner J, et al. A multi-source approach to determine SMA incidence and research ready population. J Neurol. 2017;264(7):1465-73.","journal-title":"J Neurol"},{"issue":"1","key":"key20241114131604_B12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s00415-013-7154-1","article-title":"Mapping the differences in care for 5,000 spinal muscular atrophy patients: A survey of 24 national registries in North America, Australasia and Europe","volume":"261","author":"Bladen","year":"2014","unstructured":"12. Bladen CL, Thompson R, Jackson JM, Connie Guirlanda C, Wegel C, Ambrosini A, et al. Mapping the differences in care for 5,000 spinal muscular atrophy patients: A survey of 24 national registries in North America, Australasia and Europe. J Neurol. 2014;261(1):152-63.","journal-title":"J Neurol"},{"issue":"1","key":"key20241114131604_B13","article-title":"Consensus from the Brazilian Academy of Neurology for the diagnosis, genetic counseling, and use of disease-modifying therapies in 5q spinal muscular atrophy","volume":"82","author":"Zanoteli","year":"2024","unstructured":"13. Zanoteli E, Araujo AP, Becker MM, Fortes CP, Fran\u00e7a Jr MC, Machado-Costa MC, et al. Consensus from the Brazilian Academy of Neurology for the diagnosis, genetic counseling, and use of disease-modifying therapies in 5q spinal muscular atrophy. Arq. Neuropsiquiatr. 2024;82(1):s00441779503.","journal-title":"Arq. Neuropsiquiatr"},{"key":"key20241114131604_B14","author":"ClinicalTrials.gov","unstructured":"14. ClinicalTrials.gov. NCT04404764: Characterization of the clinical-epidemiological profile of patients with SMA5q types II and III: Observational study. [cited 2024 Ago 14]. Available from: http:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04404764","journal-title":"NCT04404764: Characterization of the clinical-epidemiological profile of patients with SMA5q types II and III: Observational study"},{"issue":"7","key":"key20241114131604_B15","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9072222","article-title":"New treatments in spinal muscular atrophy: Positive results and new challenges","volume":"9","author":"Messina","year":"2020","unstructured":"15. Messina S, Sframeli M. New treatments in spinal muscular atrophy: Positive results and new challenges. J Clin Med. 2020;9(7):2222. Review.","journal-title":"J Clin Med"},{"issue":"1","key":"key20241114131604_B16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5603\/PJNNS.a2019.0068","article-title":"Spinal muscular atrophy-New therapies, new challenges","volume":"54","author":"Jedrzejowska","year":"2020","unstructured":"16. Jedrzejowska M, Kostera-Pruszczyk A. Spinal muscular atrophy-New therapies, new challenges. Neurol Neurochir Pol. 2020;54(1):8-13.","journal-title":"Neurol Neurochir Pol"}],"container-title":["einstein (S\u00e3o Paulo)"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T13:16:22Z","timestamp":1731590182000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.einstein.br\/article\/longitudinal-data-collection-in-pediatric-and-adult-patients-with-5q-spinal-muscular-atrophy-in-latin-america-latam-registrame-study-a-clinical-registry-study-protocol\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":16,"alternative-id":["10.31744\/einstein_journal\/2024AE1133"],"URL":"https:\/\/doi.org\/10.31744\/einstein_journal\/2024ae1133","relation":{},"ISSN":["1679-4508","2317-6385"],"issn-type":[{"value":"1679-4508","type":"print"},{"value":"2317-6385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"eAE1133"}}